Who are Minerva Neurosciences, Inc.'s main suppliers?

Minerva Neurosciences, Inc. (NERV) key suppliers include: MTPC, TANABE-PHARMA-CORPORATION. View the full supplier network at chainsifter.com/chain/NERV.

Who are Minerva Neurosciences, Inc.'s major customers?

Minerva Neurosciences, Inc. (NERV) key customers include: JANSSEN, Johnson & Johnson, Johnson & Johnson, Royalty Pharma plc, Royalty Pharma plc and 7 more. View the full customer network at chainsifter.com/chain/NERV.

What sector is Minerva Neurosciences, Inc. in?

Minerva Neurosciences, Inc. (NERV) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Minerva Neurosciences, Inc. (NERV) Supply Chain: 17 Verified Relationships

2Suppliers

12Customers

3Debt Items

20Related Chains

Source-Backed Evidence Depth

Minerva Neurosciences, Inc. (NERV) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

18Total relationships

3Distinct source URLs

7High confidence

0.763Average confidence

2026-09-13Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Minerva Neurosciences, Inc. Suppliers

Ticker	Name	Confidence	Evidence
MTPC	MTPC	92%	We have entered into a license agreement with MTPC dated as of August 30, 2007, as amended
TANABE-PHARMA-CORPORATION	TANABE-PHARMA-CORPORATION	90%	We will pay Tanabe Pharma a tiered royalty for net sales of product by us or any of our affiliates or sublicensees containing the licensed compound

Minerva Neurosciences, Inc. Customers

Ticker	Name	Confidence	Evidence
JANSSEN	JANSSEN	90%	We have only generated collaborative revenue due to opting out of our license and co-development agreement with Janssen.
JNJ	Johnson & Johnson	72%	ntly expect topline efficacy results in the second half of 2027 and relapse assessment data in the second half of 2028. In addition, we previously co-developed seltorexant with Janssen Pharmaceutica …
JNJ	Johnson & Johnson	72%	Reciprocal relationship from JNJ graph: Reciprocal relationship from NERV graph: ntly expect topline efficacy results in the second half of 2027 and relapse assessment data in the second half of 2028…
RPRX	Royalty Pharma plc	72%	Reciprocal relationship from RPRX graph: Reciprocal relationship from NERV graph: pment of seltorexant and as a result, we were entitled to collect royalties in the mid-single digits on potential fut…
RPRX	Royalty Pharma plc	72%	pment of seltorexant and as a result, we were entitled to collect royalties in the mid-single digits on potential future worldwide sales of seltorexant in certain indications, with no further financi…
SNYNF	Sanofi	72%	Reciprocal relationship from SNYNF graph: Reciprocal relationship from NERV graph: ms represent a significant debilitating, unmet need; 6 • Selectively explore collaborations with leading pharmaceuti…
SNYNF	Sanofi	72%	ms represent a significant debilitating, unmet need; 6 • Selectively explore collaborations with leading pharmaceutical companies to maximize the value of our current product candidate portfolio, par…
ALL-WALES-MEDICINES-STRATEGY-GROUP	ALL-WALES-MEDICINES-STRATEGY-GROUP	62%	on among EU Member States in assessing health technologies, 42 including new medicinal products, and provides the basis for cooperation at EU level for joint clinical assessments in these areas. The …
CYRENAIC-PHARMACEUTICALS-INC	CYRENAIC-PHARMACEUTICALS-INC	62%	ms represent a significant debilitating, unmet need; 6 • Selectively explore collaborations with leading pharmaceutical companies to maximize the value of our current product candidate portfolio, par…
LUYE-PHARMA-GROUP	LUYE-PHARMA-GROUP	62%	ms represent a significant debilitating, unmet need; 6 • Selectively explore collaborations with leading pharmaceutical companies to maximize the value of our current product candidate portfolio, par…
MITSUBISHI-TANABE-PHARMA-CORPORATION	MITSUBISHI-TANABE-PHARMA-CORPORATION	62%	ms represent a significant debilitating, unmet need; 6 • Selectively explore collaborations with leading pharmaceutical companies to maximize the value of our current product candidate portfolio, par…
SONKEI-PHARMACEUTICALS-INC	SONKEI-PHARMACEUTICALS-INC	62%	ates, commercial market estimates, future development efforts, patent protection, effects of healthcare reform, reliance on third parties, and other risks set forth below. Risks Related to Our Financ…

Minerva Neurosciences, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
NERV-DEBT	Debt stack $9.4M	90%	Market cache reports total debt of $9.4M.
NERV-DEBT-11220	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2025-12-31.
NERV-DEBT-11219	Warrants outstanding: 166344	90%	xbrl warrant detail from xbrl 2025-12-31.

Minerva Neurosciences, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Minerva Neurosciences, Inc..

Minerva Neurosciences, Inc. Ownership

Holder	Name	Confidence	Evidence
NERV-OWNER-VIVO-CAPITAL-LLC	Vivo Capital, LLC	90%	13F overlay lists Vivo Capital, LLC as top holder; 44 tracked holders.

Minerva Neurosciences, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops
DSGN	Design Therapeutics, Inc.	100.00	2
CSTE	Caesarstone Ltd.	100.00	2
BNR	Burning Rock Biotech Limited	100.00	2
CCEP	Coca-Cola Europacific Partners PLC	100.00	2
BLRX	BioLineRx Ltd.	100.00	2
AZN	AstraZeneca PLC	100.00	2
BLLN	BillionToOne, Inc.	100.00	2
SVA	Sinovac Biotech Ltd.	100.00	2
BNRG	Brenmiller Energy Ltd	100.00	2
ANRO	Alto Neuroscience, Inc.	100.00	2
AORT	Artivion, Inc.	100.00	2
AVBP	ArriVent BioPharma, Inc.	100.00	2
CYTOF	Altamira Therapeutics Ltd.	100.00	2
ANIK	Anika Therapeutics, Inc.	100.00	2
BIOA	BioAge Labs, Inc.	100.00	2
CYTK	Cytokinetics, Incorporated	100.00	2
ANL	Adlai Nortye Ltd.	100.00	2
CBIO	Crescent Biopharma, Inc.	100.00	2
ALXO	ALX Oncology Holdings Inc.	100.00	2
DBVTF	DBV TECHNOLOGIES	100.00	2

Minerva Neurosciences, Inc. Supply Chain